CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
CANADA

About Us

Conference

Partner With Us

  • APAC
    • US
    • EUROPE
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    Bioinformatics & Genomics
    BioTech
    Cell and Gene Therapy
    Drug Discovery and Development
    Life Science AI
    Next-Generation Sequencing
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    CDMO
    Cosmetic
    CRO
    Life Science Testing And Compliance
    Supplement Manufacturing
  • Business Services
    Life Science Consulting
    Life Sciences Marketing and Communication
  • Leadership Perspectives
  • Innovation Insights
  • News
  • Magazines
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

NADMED Ltd. has been recognized by Life Sciences Review Magazine as the exclusive recipient of “Top 10 Clinical Laboratory Services Companies in Europe - 2022,” based on our proprietary methodology, reflecting its position in the industry. This profile has been developed by the Life Sciences Review research and editorial team based on insights from an interview with , .

NADMED Ltd.
Setting the Standard in NAD Profiling

NADMED Ltd.

Jana Buzkova, Chief Operating Officer, NADMED Ltd.Jana Buzkova, Chief Operating Officer
NAD+ (a critical coenzyme) is one of the most widespread and biologically most important activators within the plant and animal world,” said Euler-Chelpin, who won the 1929 Nobel Prize for Chemistry jointly with Arthur Harden.

Recent studies have shown that changes in the levels of NAD+ and its related metabolites (NADome) can indicate the performance of the metabolic function. The challenge, however, lies in measuring the level of NADs as they are difficult to extract from biological fluids, preventing accurate quantitation. NADMED has overcome this challenge by accurately measuring all four forms of NAD directly from blood using an innovative non-destructive extraction methodology.

“The technology was invented during an effort to meet the requirements of research on mitochondrial disorders. It became a need when we wanted to monitor the effect of the vitamin B3 supplement on patients´ NAD levels,” says Jana Buzkova, Chief Operating Officer at NADMED.

Liliya Euro, the Chief Scientist at the company, took the challenge at the University of Helsinki and started developing the technology, which was meant mainly for cells or tissues of mice. Eventually, she was able to extract NAD from human blood and tissue.

Leveraging its groundbreaking technology, NADMED provides a tool for clinical trials and research by pharma companies, offering more profound insights into metabolism. The company helps the research community tap into the NAD knowledge at different levels.

Companies developing drugs or conducting clinical trials can utilize the knowledge to make decisions for better effectiveness of drugs or higher success rate of the trials.

NADMED currently provides two types of NAD measurement kits in two different variants. It offers Q-NADMED Blood Kit, a quantitative assay kit for NAD+ and NADH in blood. It is an CE marked in-vitro diagnostic medical device applicable in clinical laboratories that measures concentrations of NAD+ and NADH metabolites in human blood. The company also offers another kit (Q-NAD tissue/cells Kit) to measure these metabolites through tissue or cells. For measuring NADP+ and NADPH, NADMED provides Q-NADP Blood Kit, which also comes in another variant for measurement through tissue or cells.

NADMED sets the standard in this field by getting an accurate measurement in the first attempt. It also offers laboratory services to support research and drug development.

The technology was invented during an effort to meet the requirements of research on mitochondrial disorders. It became a need when we wanted to monitor the effect of the vitamin B3 supplement on patients´ NAD levels

Helping the researchers analyze the NADs accurately, NADMED empowers them in their endeavour of developing drugs and conducting clinical trials. In the case of drug development, understanding the impact on basic metabolism is of the essence. NADMED helps drug developers assess the level of NADs as they are tightly involved in energy production, which sequentially is crucial for body´s drug responses. As for clinical trials, NAD levels can potentially be used as a biomarker to assess the individual’s responsiveness to the treatment modality in question. NADMED helps companies identify sub-population of patients who might respond better to the intervention. Such insights can improve the success of the trials due to more accurate patient selection.

Going from strength to strength, NADMED plans to provide glutathione kits as well and is currently involved in developing the kits for the market. The service provides a comprehensive measurement of six analytes from a single sample.

Top 10 Clinical Laboratory Services Companies in Europe - 2022
Current Issue

Company : NADMED Ltd.

Management
Jana Buzkova, Chief Operating Officer

Thank you for Subscribing to Life Science Review Weekly Brief

Life Sciences Review APAC
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review APAC. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreviewapac.com/nadmed-ltd